Sex: M
Vaccine: COVID19, COVID19
Symptoms: COVID-19, Interchange of vaccine products
Clinical narrative: Diagnosed with COVID-19 after receiving primary series of Moderna COVID-19 Vaccine and a Pfizer booster; Received primary series of Moderna Covid19 vaccine and a Pfizer booster; This spontaneous case was reported by a pharmacist and describes the occurrence of COVID-19 (Diagnosed with COVID-19 after receiving primary series of Moderna COVID-19 Vaccine and a Pfizer booster) and INTERCHANGE OF VACCINE PRODUCTS (Received primary series of Moderna Covid19 vaccine and a Pfizer booster) in a male patient of an unknown age who received mRNA-1273 (Spikevax) for COVID-19 vaccination.    Co-suspect product included non-company product TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) for an unknown indication.    No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form On an unknown date, received first dose of mRNA-1273 (Spikevax) (Intramuscular) dosage was changed to 1 dosage form. and third dose of TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) (unknown route) 1 dosage form. On an unknown date, the patient experienced COVID-19 (Diagnosed with COVID-19 after receiving primary series of Moderna COVID-19 Vaccine and a Pfizer booster) and INTERCHANGE OF VACCINE PRODUCTS (Received primary series of Moderna Covid19 vaccine and a Pfizer booster). At the time of the report, COVID-19 (Diagnosed with COVID-19 after receiving primary series of Moderna COVID-19 Vaccine and a Pfizer booster) and INTERCHANGE OF VACCINE PRODUCTS (Received primary series of Moderna Covid19 vaccine and a Pfizer booster) outcome was unknown.        For mRNA-1273 (Spikevax) (Unknown), the reporter did not provide any causality assessments.   Concomitant medication information was not provided by the reporter.  Patient received Pfizer booster vaccine.  Treatment information was not provided by the reporter.  Company Comment: This spontaneous case concerns a male patient of unknown age, with no reported medical history, who experienced unexpected, non-serious AESI Covid19 on an unknown date after receiving mRNA-1273.  It was reported that the patient was diagnosed with Covid19 after receiving mRNA-1273 as primary series and Pfizer as booster (interchange of vaccine products).  Clinical course, labs, concomitant medications, and treatment details not reported.  The outcome was unknown.  The ongoing Covid19 pandemic could be a contributory factor.  The benefit risk relationship of mRNA-1273 is not affected by this report.; Sender's Comments: This spontaneous case concerns a male patient of unknown age, with no reported medical history, who experienced unexpected, non-serious AESI Covid19 on an unknown date after receiving mRNA-1273.  It was reported that the patient was diagnosed with Covid19 after receiving mRNA-1273 as primary series and Pfizer as booster (interchange of vaccine products).  Clinical course, labs, concomitant medications, and treatment details not reported.  The outcome was unknown.  The ongoing Covid19 pandemic could be a contributory factor.  The benefit risk relationship of mRNA-1273 is not affected by this report.